Torray Investment Partners LLC Increases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Torray Investment Partners LLC raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,078 shares of the medical equipment provider’s stock after purchasing an additional 1,560 shares during the period. Torray Investment Partners LLC’s holdings in Lantheus were worth $2,094,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC lifted its position in Lantheus by 24.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 52,864 shares of the medical equipment provider’s stock worth $4,244,000 after buying an additional 10,388 shares during the last quarter. UNIVEST FINANCIAL Corp boosted its stake in shares of Lantheus by 37.9% in the 2nd quarter. UNIVEST FINANCIAL Corp now owns 5,528 shares of the medical equipment provider’s stock valued at $444,000 after purchasing an additional 1,519 shares in the last quarter. Foundry Partners LLC bought a new position in shares of Lantheus during the 2nd quarter valued at $488,000. Arizona State Retirement System raised its position in Lantheus by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 19,190 shares of the medical equipment provider’s stock worth $1,541,000 after purchasing an additional 368 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Lantheus by 18.5% in the second quarter. Victory Capital Management Inc. now owns 25,705 shares of the medical equipment provider’s stock worth $2,064,000 after purchasing an additional 4,021 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 3.2 %

Shares of LNTH traded down $3.36 during trading hours on Friday, reaching $101.98. 561,405 shares of the company traded hands, compared to its average volume of 1,036,350. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The company’s fifty day moving average price is $102.61 and its two-hundred day moving average price is $81.26. The company has a market capitalization of $7.07 billion, a price-to-earnings ratio of 15.57 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. During the same period in the previous year, the company earned $1.40 earnings per share. Lantheus’s revenue for the quarter was up 22.5% on a year-over-year basis. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.03 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the sale, the chief accounting officer now directly owns 62,557 shares of the company’s stock, valued at approximately $4,990,171.89. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total transaction of $27,201.57. Following the sale, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The disclosure for this sale can be found here. Insiders sold a total of 41,193 shares of company stock valued at $3,949,202 in the last three months. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of recent research reports. Truist Financial reduced their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Leerink Partners lifted their price target on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. B. Riley increased their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. JMP Securities decreased their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. Finally, Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday. They set a “buy” rating and a $175.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.